Polynomial equations have long served as a cornerstone of mathematical analysis, offering a framework to understand functions, curves, and dynamic systems. In recent years, the study of these ...

After 5 years, Kisqali® plus endocrine therapy consistently shows significant and clinically meaningful benefit in invasive disease-free survival1 Kisqali remains the only CDK4/6 inhibitor ...

MARLBOROUGH, Mass., December 09, 2024--(BUSINESS WIRE)--Four new studies regarding the Breast Cancer Index (BCI) test will be presented at the 2024 San Antonio Breast Cancer Symposium (SABCS). Among ...

Recent advances in healthcare research have increasingly leveraged routinely collected administrative data to monitor cancer recurrence. This approach circumvents the delays and resource-intensive ...

Phase II Study of Paclitaxel Plus Gemcitabine in Refractory Germ Cell Tumors (E9897): A Trial of the Eastern Cooperative Oncology Group PURPOSE: To assess the effect of nerve-sparing (NS) radical ...

This is a preview. Log in through your library . Abstract The stability analysis for numerical methods provides insight into their suitability in practice. A stability condition involving the spectral ...

Access to Genetic Testing Impacts Oncologists´ Decisions on Ovarian Cancer Personalized Treatment: Lessons Learned From a National Program in Greece Data for reporting system-wide treatment activity ...

We consider two semiclassical extensions of the Laguerre weight and their associated sets of orthogonal polynomials. These polynomials satisfy a three-term recurrence relation. We show that the ...

- Five-year outcomes from large, prospective phase III ADAPT study confirm value of the test to help guide treatment decisions in breast cancer patients with high clinical risk, including those with ...

Impact of two years of adjuvant Verzenio treatment is observed well beyond the treatment period, reducing the risk of long-term recurrence by 32% and improving invasive disease-free survival by 7.6% ...

Patients with breast cancer want accurate information on the risk of their cancer recurring once they have completed treatment. "I would like to know the true stats of how many breast cancers come ...

Forty-three percent of trials did not include data on post-recurrence treatment. Researchers identified a lack of data on post-recurrence treatment in trials supporting recent approvals of ...